The treatment of head and neck squamous cell carcinoma (HNSCC) has been a medical challenge with limited improvement in overall survival over the past few decades. However, recently, very interesting innovations in the field of immunotherapy have been shown to be beneficial for patients with advanced HNSCC. In this article, the latest medical developments are reviewed with special focus on the clinical achievements and current clinical studies in the field of immunotherapy. The landscape of clinical studies has changed considerably from antibody-based growth factor inhibition towards immune checkpoint modulation, and new indications in the adjuvant and neoadjuvant setting are being tested in large patient cohorts. Even the combination of 2 or more immune modulatory approaches and the correct synchronization with standard cancer therapy is promising and warrants suitable clinical trials.

Journal Section:
Review Article
Keywords:
HNSCC, Immunotherapy, PD-1, Immune escape, Vaccination
1.
Schuler PJ, Hoffmann TK, Gauler TC, et al.: Immunotherapy of head and neck cancer. Current developments (in German). HNO 2013;61:559-572.
2.
Alexandrov LB, Nik-Zainal S, Wedge DC, et al.: Signatures of mutational processes in human cancer. Nature 2013;500:415-421.
3.
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW: Cancer genome landscapes. Science 2013;339:1546-1558.
4.
Hoffmann TK, Sonkoly E, Hauser U, van Lierop A, Whiteside TL, Klussmann JP, Hafner D, Schuler P, Friebe-Hoffmann U, Scheckenbach K, Erjala K, Grenman R, Schipper J, Bier H, Balz V: Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 2008;44:1100-1109.
5.
Dietz A, Loeffler M, Rosolowski M, et al.: Gene expression analyses and their possible clinical benefit in head and neck cancer (in German). HNO 2015;63:773-785.
6.
Hoffmann TK, Schuler PJ: Antigen-specific immunotherapy in head and neck cancer. Adv Cell Mol Otolaryngol 2013;1.
7.
Freeman SM, Franco JL, Kenady DE, et al.: A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol 2011;34:173-178.
8.
Timar J, Forster-Horvath C, Lukits J, et al.: The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: A possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer - a multicenter phase I/II clinical trial. Laryngoscope 2003;113:2206-2217.
9.
Morishima C, Miller JS: CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells. J Immunother Cancer 2015;3(suppl 2):203.
10.
Chow LQ, Morishima C, Eaton KD, et al.: Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN. Clin Cancer Res 2016; doi: 10.1158/1078-0432.CCR-16-1934.
11.
Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28.
12.
Tham T, White TG, Chakraborty S, Lall RR, Ortiz R, Langer DJ, Shatzkes D, Filippi CG, Kraus D, Boockvar JA, Costantino PD: Intra-arterial cetuximab for the treatment of recurrent unresectable head and neck squamous cell carcinoma. J Exp Ther Oncol 2016;11:293-301.
13.
Hartmann S, Bhola NE, Grandis JR: HGF/Met signaling in head and neck cancer: impact on the tumor microenvironment. Clin Cancer Res 2016;22:4005-4013.
14.
Ruzsa A, Sen M, Evans M, et al.: Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Invest New Drugs 2014;32:1278-1284.
15.
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
16.
Wolchok JD, Kluger H, Callahan MK, et al.: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-133.
17.
Thierauf J, Veit JA, Hess J, et al.: Checkpoint inhibition for advanced mucosal melanoma. Eur J Dermatol 2017; doi: 10.1684/ejd.2016.2949.
18.
Seiwert TY, Burtness B, Mehra R, et al.: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17:956-965.
19.
Laban S, Doescher J, Schuler PJ, et al.: Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015 (in German). HNO 2015;63:612-619.
20.
Ferris RL, Blumenschein G Jr, Fayette J, et al.: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856-1867.
21.
Postow MA: Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015;35:76-83.
22.
Antonia SJ: Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J Clin Oncol 2015;33(suppl):abstr 3014.
23.
Lui VW, Peyser ND, Ng PK, et al.: Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 2014;111:1114-1119.
24.
Uyttenhove C, Pilotte L, Theate I, et al.: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-1274.
25.
Croft M, Benedict CA, Ware CF: Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013;12:147-168.
26.
Schuler PJ, Harasymczuk M, Visus C, et al.: Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014;20:2433-2444.
27.
Karcher J, Dyckhoff G, Beckhove P, et al.: Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 2004;64:8057-8061.
28.
Zandberg DP, Rollins S, Goloubeva O, et al.: A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother 2015;64:367-379.
29.
Yoshitake Y, Fukuma D, Yuno A, et al.: Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res 2015;21:312-321.
30.
Taylor GS, Jia H, Harrington K, et al.: A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 2014;20:5009-5022.
31.
Schuler PJ, Schilling B, Harasymczuk M, et al.: Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 2012;42:1876-1885.
32.
Hoffmann TK, Muller-Berghaus J, Ferris RL, et al.: Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 2002;8:1787-1793.
33.
Smith C, Tsang J, Beagley L, et al.: Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 2012;72:1116-1125.
34.
Stevanovic S, Draper LM, Langhan MM, et al.: Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015;33:1543-1550.
35.
van der Stegen SJ, Davies DM, Wilkie S, et al.: Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: Identifying a window of therapeutic opportunity? J Immunol 2013;191:4589-4598.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.